11/11/2010

Theratechnologies has gained FDA approval of Egrifta as an injectable treatment for lipodystrophy, a condition characterized by high fat accumulation, in HIV patients. The once-daily drug, generically known as tesamorelin, will be marketed by Theratechnologies' partner Merck Serono.

Related Summaries